In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Takeda, Lilly co-promote Takeda's oral diabetes product in US

Executive Summary

In a deal aimed at getting its orally-delivered diabetes product to the US market, Takeda Chemicals will co-promote its pioglitazone in the US with Eli Lilly. Lilly will promote the drug in the US for 7 years from launch, after which Takeda will take over all promotional duties, paying Lilly a declining royalty on sales.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)
    • Product or Technology Swap

Related Companies